Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
about
Progress and problems in understanding and managing primary Epstein-Barr virus infectionsAnti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinaseInhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphomaResistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency.Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation.Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus.Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.Conserved herpesvirus protein kinases.Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screeningLong-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.Expression and localization of the Epstein-Barr virus-encoded protein kinase.Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta.The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral productionMaribavir inhibits epstein-barr virus transcription in addition to viral DNA replicationA rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus.Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 proteinSusceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosidesAntiviral Drugs for EBV.
P2860
Q24597706-91547183-8861-48D0-93FB-F9C93DA57235Q28344936-41E53683-1DFB-49AE-93F2-A027DC112907Q28362995-5E0043FC-E814-4D38-BB9C-CE3E2072FF67Q28472086-F5F35992-0AF3-4EDE-A23F-AA94FA82C6D8Q31011523-C77FE91F-1A25-45F4-B074-3A4467F941F1Q33981473-00908DC3-DEC4-4488-8F54-E26718A2907CQ34109911-8AEFBF30-73F1-42B3-8EDE-D322ED5EAC07Q34405076-9D8F1145-E7DB-4E5E-941B-B7448BB157A9Q34742654-9C7A4285-4A9F-4358-AD25-E3828306383AQ35103227-58867578-536B-4A61-A5CC-0591D3940551Q35857562-D51E40C0-8D2B-4688-8519-5BB5CE0296A6Q36442795-04D1320D-4CEC-4EF9-A121-1BFA9E1D8C72Q36491044-DA9008D7-18E7-4CEF-BF5E-4E8C5EBF82E7Q37278489-22A9F6E0-AA70-4526-8E71-499067DBE34CQ37410629-6064F00E-6666-482A-9DC3-C119E2203037Q37596917-3CFDC03F-2274-49C5-B740-9F1D6A765044Q37734377-EEB8AE7A-E3A9-47AF-9C15-F40CF4D14AF5Q37734561-02098F72-34C7-4B13-8622-BE94380CFB6EQ37951633-8B415D84-BD09-46A5-88DC-97226F99E65AQ39187112-6EA56CA7-1815-4B16-8E80-C1E914463509Q39682303-A1E9552B-F037-4C7E-B2B1-5B3B16D6F2CCQ39716669-2D118956-EB2E-411D-967A-6472DD96B2BEQ39735571-890C861C-16A0-4F25-B088-E06ACE2D537EQ39798789-B591B4C4-A2CC-4212-A1A8-8B8E789C93E7Q40125731-8F59CD00-9F35-493B-A4C5-C42E38934458Q40155828-466AC754-2579-4734-9907-D3ED035A1B9DQ41836415-292F47EE-11F9-420F-8EDF-96EE670FCEB2Q42687324-5ED612B0-DA91-4C38-81BC-F5990360B83AQ55461330-279360B2-A0E1-43EC-AEDC-F16795746E3F
P2860
Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Inhibition of Epstein-Barr vir ...... ribofuranosyl-1H-benzimidazole
@nl
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@ast
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@en
type
label
Inhibition of Epstein-Barr vir ...... ribofuranosyl-1H-benzimidazole
@nl
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@ast
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@en
prefLabel
Inhibition of Epstein-Barr vir ...... ribofuranosyl-1H-benzimidazole
@nl
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@ast
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@en
P2093
P2860
P1433
P1476
Inhibition of Epstein-Barr vir ...... ibofuranosyl-1H-benzimidazole.
@en
P2093
P2860
P304
P407
P577
1999-09-01T00:00:00Z